Japan & Johnson & Johnson

Japan: Aging population drives demand; home to Olympus.

Johnson & Johnson: Key player; growth forecast positive for its medical devices segment.

Japan: Japan is identified as a key market for J&J's planned global expansion of the OTTAVA system.

Johnson & Johnson: J&J received FDA authorization for its OTTAVA robotic system, marking its entry into the US soft-tissue robotic surgery market. This approval is a key milestone for its medtech business and positions it to compete with Intuitive Surgical and Medtronic.

Japan: Japan's economy is affected by the Iran war, with its stock market experiencing volatility and firms reporting sharp rises in input costs due to higher raw material prices.

Johnson & Johnson: Johnson & Johnson, a supply chain consultant, warns that the war's impact on costs will filter through supply chains for the rest of the year, leading to bigger problems if oil shortages persist.

Japan: AVT05, AVT06, and AVT03 have already been approved in Japan>>>, indicating their global market presence.

Johnson & Johnson: Johnson & Johnson>>> owns the trademarks for Simponi and Simponi Aria, the reference products for Alvogen>>>'s AVT05 biosimilar. The potential market entry of AVT05 could introduce competition to Johnson & Johnson>>>'s products.